FrancophonIA/ELRC3.0 huggingface dataset:
English: The median OS for patients with NSCLC other than predominantly squamous cell histology (N=481) was 15.5 months for the pemetrexed arm and 10.3 months for the placebo arm, hazard ratio = 0.70 (95% CI=0.56-0.88, p=0.002).
Estonian: Muu kui prevaleeruvalt lamerakulise histoloogiaga mitteväikerakkkopsuvähiga patsientidel (n=481) oli üldise elulemuse mediaan 15,5 kuud pemetrekseedi rühmas ja 10,3 kuud platseeborühmas (riskitiheduste suhe=0,70, 95% CI=0,56…0,88, p=0,002).
English: Haemoglobin decreased 33.0* Neutrophils/Granulocyte s decreased
Estonian: Hemoglobiini vähenemine Neutropeenia/ granulotsütopeeni
English: Including the induction phase, the median OS for patients with NSCLC other than predominantly squamous cell histology was 18.6 months for the pemetrexed arm and 13.6 months for the placebo arm, hazard ratio = 0.71 (95% CI=0.56-0.88, p=0.002).
Estonian: Kui induktsioonfaas kaasa arvata, oli muu kui prevaleeruvalt lamerakulise histoloogiaga mitteväikerakkkopsuvähiga patsientidel üldise elulemuse mediaan 18,6 kuud pemetrekseedi rühmas ja 13,6 kuud platseeborühmas (riskitiheduste suhe=0,71, 95% CI=0,56…0,88, p=0,002).
English: Reconstitute each 100 mg vial with 4.2 ml of 9 mg/ml (0.9%) sodium chloride solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Estonian: Lahustage 100 mg viaali sisu 4,2 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega, mis ei sisalda säilitusainet, mille tulemusena saate pemetrekseedi lahuse 25 mg/ml.
English: The appropriate volume of reconstituted pemetrexed solution must be further diluted to 100 ml with sodium chloride 9 mg/ml (0.9%) solution for injection, without preservative, and administered as an intravenous infusion over 10 minutes.
Estonian: Vastav kogus pemetrekseedi lahust tuleb lahjendada veel ilma säilitusaineta naatriumkloriidi 9 mg/ml (0,9%) süstelahusega, et saaks 100 ml valmislahust, mida manustatakse veenisisese infusioonina 10 minuti jooksul.
English: Pemetrexed Krka 500 mg powder for concentrate pemetrexed
Estonian: Pemetrexed Krka 500 mg kontsentraadi pulber pemetrexedum i.v.
English: powder for concentrate for solution for infusion
Estonian: Infusioonilahuse kontsentraadi pulber
English: Overall response rate** (95% CI)
Estonian: Logaritmilise astaktesti p-väärtus* Üldise ravivastuse määr** (95 % CI)
English: Women must use effective contraception during treatment with Pemetrexed Krka.
Estonian: Pemetrexed Krka ravi ajal peavad naised rakendama tõhusat kontratseptsiooni.
English: Pemetrexed Krka 100 mg powder for concentrate for solution for infusion Each vial contains 100 mg pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Pemetrexed Krka 100 mg infusioonilahuse kontsentraadi pulber Üks viaal sisaldab 100 mg pemetrekseedi (dinaatriumpemetrekseedhemipentahüdraadina).
English: Reconstitute each 500 mg vial with 20 ml of 9 mg/ml (0.9%) sodium chloride solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Estonian: Lahustage 500 mg viaali sisu 20 ml naatriumkloriidi 9 mg/ml (0,9%) süstelahusega, mis ei sisalda säilitusainet, mille tulemusena saate pemetrekseedi lahuse 25 mg/ml.
English: From the start of pemetrexed plus cisplatin first-line induction treatment, the median OS of patients was 16.9 months for the pemetrexed arm and 14.0 months for the placebo arm (hazard ratio = 0.78, 95% CI=0.64-0.96).
Estonian: Alates pemetreksiid/tsisplatiin esimese rea induktsioonravist oli OS mediaan pemetreksiidi grupis 16,9 kuud ja platseebogrupis 14,0 kuud (riskisuhe=0,78, 95% CI= 0,64...0,96).
English: Pemetrexed Krka 500 mg powder for concentrate for solution for infusion Each vial contains 500 mg pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Pemetrexed Krka 500 mg infusioonilahuse kontsentraadi pulber Üks viaal sisaldab 500 mg pemetrekseedi (dinaatriumpemetrekseedhemipentahüdraadina).
English: Survival time (months)
Estonian: Elulemus (kuud)
English: Pemetrexed Krka 100 mg powder for concentrate pemetrexed
Estonian: Pemetrexed Krka 100 mg kontsentraadi pulber pemetrexedum i.v.
English: Frequency* Event**
Estonian: Neerude häired****
English: A multi-centre, randomised, open-label Phase 3 study of pemetrexed versus docetaxel in patients with locally advanced or metastatic NSCLC after prior chemotherapy has shown median survival times of 8.3 months for patients treated with pemetrexed (Intent-To-Treat [ITT] population N=283) and 7.9 months for patients treated with docetaxel (ITT N=288).
Estonian: näitas keskmist elulemust - pemetrekseedi patsientidel 8,3 kuud [ravikavatsusega (ITT) populatsioon n=283] ja dotsetakseeli patsientidel 7,9 kuud (ITT n=288).
English: Pemetrexed Krka 100 mg powder for concentrate for solution for infusion Pemetrexed Krka 500 mg powder for concentrate for solution for infusion pemetrexed
Estonian: Pemetrexed Krka 100 mg infusioonilahuse kontsentraadi pulber Pemetrexed Krka 500 mg infusioonilahuse kontsentraadi pulber
English: Intravenous use after reconstitution and dilution.
Estonian: Pärast manustamiskõlblikuks muutmist ja lahjendamist veenisiseseks kasutamiseks.
English: Cisplatin (N=222)
Estonian: (N=222)
English: Therefore, caution should be made when administering higher doses of NSAIDs or acetylsalicylic acid, concurrently with pemetrexed to patients with normal function (creatinine clearance ≥ 80 ml/min).
Estonian: Normaalse neerufunktsiooniga patsientidel (kreatiniini kliirens ≥ 80 ml/min), kellele manustatakse pemetrekseedi, tuleb ettevaatusega kasutada MSPVA-sid või atsetüülsalitsüülhapet suuremates annustes.
English: Pemetrexed Krka 500 mg powder for concentrate for solution for infusion pemetrexed
Estonian: Pemetrexed Krka 500 mg infusioonilahuse kontsentraadi pulber pemetrexedum
English: Pemetrexed Krka 100 mg powder for concentrate for solution for infusion pemetrexed
Estonian: Pemetrexed Krka 100 mg infusioonilahuse kontsentraadi pulber pemetrexedum
English: NSCLC, second-line treatment
Estonian: Mitteväikerakkkopsuvähk, teise valiku ravi
English: The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in > 5% of 839 patients with NSCLC who were randomized to receive cisplatin and pemetrexed and 830 patients with NSCLC who were randomized to receive cisplatin and gemcitabine.
Estonian: Alljärgnevas tabelis on esitatud kõrvaltoimete esinemissagedus ja raskusaste, millel arvati võimalikku seost uuringuravimiga ja mida täheldati rohkem kui 5%-l 839-st mitteväikerakk-kopsuvähki
English: Cisplatin (N=163)
Estonian: (N=163)
English: Hepatobiliary disorders
Estonian: Leukopeenia Trombotsütopeeni
English: Nadir platelets < 50,000/mm 3 with bleeding a,
Estonian: Madalaim trombotsüütide arv < 50 000/ mm verejooksu puhul a, vaatamata madalaimale neutrofiilide absoluutarvule.
English: ANC
Estonian: KARP
English: CTC
Estonian: Tsütostaatikum
English: • Response rate (%) (95% CI)
Estonian: Ravivastus (n: vastusena kvalifitseeritav) Ravivastuse määr (%) (95% CI) Haigus stabiilne (%)
English: Efficacy of pemetrexed vs. docetaxel in NSCLC - ITT population
Estonian: Pemetrekseedi ja dotsetakseeli efektiivsuse võrdlus MVRKV patsientide ITT populatsioonil
English: Each vial contains 100 mg pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Üks viaal sisaldab 100 mg pemetrekseedi (dinaatriumpemetrekseedhemipentahüdraadina).
English: Pemetrexed
Estonian: Pemetrekseed
English: Each vial contains 500 mg pemetrexed (as pemetrexed disodium hemipentahydrate).
Estonian: Üks viaal sisaldab 500 mg pemetrekseedi (dinaatriumpemetrekseedhemipentahüdraadina).
English: Loxicom received a marketing authorisation valid throughout the EU on 10 February 2009.
Estonian: Loxicomi müügiluba, mis kehtib kogu Euroopa Liidus, anti 10. veebruaril 2009.
English: Further information on Loxicom can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/loxicom.
Estonian: Lisateave Loxicomi kohta on ameti veebilehel: ema.europa.eu/medicines/veterinary/EPAR/loxicom.
English: Loxicom (meloxicam)
Estonian: Loxicom (meloksikaam)
English: Other information about Loxicom
Estonian: Muu teave Loxicomi kohta
English: As for every medicine, the company provided studies on the quality of Loxicom.
Estonian: Nagu iga ravimi korral, esitas ettevõte Loxicomi kvaliteedi uuringud.
English: What is Loxicom and what is it used for?
Estonian: Mis on Loxicom ja milleks seda kasutatakse?
English: The European Medicines Agency concluded that, in accordance with EU requirements, Loxicom has been shown to have comparable quality and to be bioequivalent to Metacam.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Loxicom võrdväärne kvaliteet ja bioekvivalentsus Metacamiga.
English: For the 20 mg/ml solution for injection the meat withdrawal period is five days, and for the 50 mg/ml oral paste it is three days.
Estonian: 20 mg/ml süstelahuse manustamisel on liha keeluaeg 5 päeva ning 50 mg/ml suukaudse pasta manustamisel 3 päeva.
English: Loxicom is an anti-inflammatory medicine used in cattle, pigs, horses, dogs and cats.
Estonian: Loxicom on põletikuvastane ravim, mida kasutatakse veistel, sigadel, hobustel, koertel ja kassidel.
English: An overview of Loxicom and why it is authorised in the EU
Estonian: Loxicomi ülevaade ja Euroopa Liidus heakskiitmise põhjused
English: For meat the withdrawal period is five days.
Estonian: Liha keeluaeg on 5 päeva.
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Metacam, and do not need to be repeated for Loxicom.
Estonian: Võrdlusravimiga Metacam on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ja neid ei ole vaja Loxicomiga korrata.
English: This means that Loxicom contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Metacam.
Estonian: See tähendab, et Loxicom sisaldab sama toimeainet ja toimib samal viisil kui võrdlusravim Metacam, millel juba on Euroopa Liidus müügiluba.
English: Because Loxicom is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Loxicom on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: As prostaglandins trigger inflammation, pain, exudation (fluid that leaks out of blood vessels during an inflammation) and fever, meloxicam reduces these signs of disease.
Estonian: Et prostaglandiinid tekitavad põletikku, valu, eksudatsiooni (põletiku korral veresoontest väljaimbuv vedelik) ja palavikku, vähendab meloksikaam neid haigussümptomeid.
English: For further information about using Loxicom, see the package leaflet or contact your veterinarian or pharmacist.
Estonian: Kui vajate Loxicomiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma veterinaararsti või apteekri poole.
English: The withdrawal period is 15 days for meat and five days for milk.
Estonian: Liha keeluaeg on 15 päeva ja piima keeluaeg on 5 päeva.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Loxicom, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Loxicomi ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: Loxicom contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Estonian: Loxicom sisaldab meloksikaami, mis kuulub mittesteroidsete põletikuvastaste ravimite (NSAID) klassi.
English: Therefore, the Agency's view was that, as for Metacam, the benefit of Loxicom outweighs the identified risk and it can be authorised for use in the EU.
Estonian: Seetõttu on amet arvamusel, et nagu ka Metacami korral, ületab ravimi Loxicom kasulikkus sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Loxicom contains the active substance meloxicam and is a ‘generic medicine'.
Estonian: Loxicom sisaldab toimeainena meloksikaami ja on geneeriline ravim.
English: What are the benefits and risks of Loxicom?
Estonian: Milles seisneb Loxicomi kasulikkus ja mis riskid ravimiga kaasnevad?
English: How is Loxicom used?
Estonian: Kuidas Loxicomi kasutatakse?
English: How does Loxicom work?
Estonian: Kuidas Loxicom toimib?
English: Loxicom can only be obtained with a prescription.
Estonian: Loxicom on retseptiravim.
English: How has Loxicom been studied?
Estonian: Kuidas Loxicomi uuriti?
English: In pigs, Loxicom is used to reduce lameness and inflammation in non-infectious locomotor disorders (diseases that affect the ability to move that are not caused by an infection) and to support together with appropriate antibiotic therapy the treatment of diseases that occur after farrowing (giving birth) such as puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome).
Estonian: Sigadel kasutatakse Loxicomi mittenakkuslike lokomotoorikahäiretega (liikumisvõimet piiravad haigused) seotud lonkamise ja põletikusümptomite vähendamiseks ning poegimisjärgsete haiguste, nt poegimisjärgse sepsise (veremürgistuse) ja tokseemia (mastiidi-metriidi-agalaktia sündroomi) toetavaks raviks koos sobiva antibiootikumraviga.
English: Why is Loxicom authorised in the EU?
Estonian: Miks anti Loxicomi müügiluba?
English: In horses, Loxicom is used to reduce pain associated with colic (abdominal pain) and to lessen inflammation and relieve pain in acute and chronic musculo-skeletal disorders (disorders affecting the muscles and bones).
Estonian: Hobustel kasutatakse Loxicomi voolmete (kõhuvalu) ning põletiku ja valu leevendamiseks ägedate ja krooniliste luu- ja lihaskonna vaevuste korral.
English: In cats, Loxicom is used to reduce pain and inflammation after ovariohysterectomy (spaying operation), orthopaedic and minor soft tissue surgery.
Estonian: Kassidel kasutatakse Loxicomi valu ja põletiku leevendamiseks pärast steriliseerimist (munasarjade ja emaka eemaldamist), ortopeedilisi operatsioone ja väikesi pehmete kudede operatsioone.
English: In dogs, Loxicom is used to reduce pain and inflammation following orthopaedic (e.g. fracture operation) and soft tissue surgery.
Estonian: Koertel kasutatakse Loxicomi valu ja põletiku leevendamiseks ortopeediliste operatsioonide (nt luumurru operatsioonide) ja pehmete kudede operatsioonide järel.
English: It can be used with oral re-hydration therapy (fluids given by mouth to restore water levels in the body) to reduce diarrhoea in calves of over one week of age and young, non-lactating cattle.
Estonian: Seda tohib kasutada kõhulahtisuse leevendamiseks koos suukaudse rehüdratsioonraviga (organismi vedelikusisaldust taastav ravi) üle nädala vanustel vasikatel ja mullikatel.
English: Loxicom is available as an oral (taken by mouth) suspension, oral paste, chewable tablets and a solution for injection.
Estonian: Loxicomi turustatakse suukaudse suspensiooni, suukaudse pasta, närimistablettide ja süstelahusena.
English: In cattle, Loxicom is used together with appropriate antibiotic therapy, to reduce clinical signs of acute respiratory infection (infection of the lungs and airways).
Estonian: Veistel kasutatakse Loxicomi ägeda respiratoorse infektsiooni (kopsude ja hingamisteede nakkuse) kliiniliste sümptomite vähendamiseks koos sobiva antibiootikumraviga.
English: It can be used to relieve pain following dehorning in calves and to support the treatment of acute mastitis (inflammation of the udder), in combination with antibiotics.
Estonian: Loxicomi tohib kasutada vasikatel nudistamisjärgse valu leevendamiseks ja ägeda mastiidi (udarapõletik) toetava ravina koos antibiootikumidega.
English: Moreover, it is used to lessen inflammation and pain in musculoskeletal disorders.
Estonian: Loxicomi kasutatakse ka põletiku ja valu leevendamiseks luu- ja lihaskonna vaevuste korral.
English: The precautions are the same as for the reference medicine since Loxicom is a generic medicine.
Estonian: Et Loxicom on geneeriline ravim, siis on meetmed samad, mis võrdlusravimi korral.
English: h-4197-AA-en
Estonian: h-4197-AA-et
English: Further information on Zykadia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Zykadia kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The average length of response was 8.3 months.
Estonian: Ravivastuse keskmine kestus oli 8,3 kuud.
English: The recommended dose is 450 mg (3 capsules) once a day taken with food at the same time each day.
Estonian: Soovitatav annus on 450 mg (3 kapslit) ööpäevas koos toiduga iga päev samal ajal.
English: What measures are being taken to ensure the safe and effective use of Zykadia?
Estonian: Mis meetmed võetakse, et tagada Zykadia ohutu ja efektiivne kasutamine?
English: The European Medicines Agency therefore decided that Zykadia's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Zykadia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Zykadia (ceritinib)
Estonian: Zykadia (tseritiniib)
English: This was switched to full marketing authorisation on 26 July 2017.
Estonian: Tingimuslik müügiluba muudeti tavaliseks müügiloaks 26. juulil 2017.
English: Zykadia received a conditional marketing authorisation valid throughout the EU on 06 May 2015.
Estonian: Zykadia on saanud müügiloa tingimusliku heakskiidu alusel, mis kehtib kogu ELis, 6. mail 2015.
English: Other information about Zykadia
Estonian: Muu teave Zykadia kohta
English: In the second study, the overall response rate was 41% (57 of 140 patients) and the average length of response was 10.6 months.
Estonian: Teises uuringus oli üldine ravivastuse määr 41% (57 patsienti 140st) ja ravivastuse keskmine kestus oli 10,6 kuud.
English: In two of these studies, involving 303 patients, the medicine was not compared with any other treatment.
Estonian: Neist kahes uuringus (303 patsienti) ei võrreldud ravimit ühegi teise raviga.
English: What is Zykadia and what is it used for?
Estonian: Mis on Zykadia ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Zykadia are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Zykadia kasutamise kohta pidevat järelevalvet.
English: Regarding safety, the adverse effects with Zykadia generally appeared manageable.
Estonian: Ohutusega seoses näisid Zykadia kõrvalnähud olevat üldiselt hallatavad.
English: Side effects reported with Zykadia are carefully evaluated and any necessary action taken to protect patients.
Estonian: Zykadia kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: In the third study in 231 patients, Zykadia was compared with standard chemotherapy (medicines to treat cancer).
Estonian: Kolmandas uuringus (231 patsienti) võrreldi Zykadiat standardse keemiaraviga (vähiravimid).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zykadia have been included in the summary of product characteristics and the package leaflet.
Estonian: Zykadia ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What are the risks associated with Zykadia?
Estonian: Mis riskid Zykadiaga kaasnevad?
English: The most common side effects with Zykadia (which may affect 1 or more people in 10) are diarrhoea, nausea (feeling sick), vomiting, tiredness, abnormal liver tests, abdominal (belly) pain, decreased appetite, weight loss, constipation, rash, increases in the level of a waste product called creatinine in the blood (a possible sign of kidney problems), oesophageal disorder (problems affecting the food pipe) and anaemia (low levels of red blood cells).
Estonian: Zykadia kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on kõhulahtisus, iiveldus, oksendamine, väsimus, ebanormaalsed maksanäitajad, kõhuvalu, isutus, kehakaalu langus, kõhukinnisus, lööve, jääkaine kreatiniini sisalduse suurenemine veres (neeruprobleemide võimalik näht), söögitoru häired ja aneemia (erütrotsüütide ehk vere punaliblede vähesus).
English: For more information about using Zykadia, see the package leaflet or contact a doctor or pharmacist.
Estonian: Lisateavet Zykadia kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The most common severe reactions (which may affect 1 or more people in 20) are abnormal liver tests, tiredness, diarrhoea, nausea, vomiting and hyperglycaemia (high blood sugar).
Estonian: Kõige sagedamad rasked reaktsioonid (võivad enam kui 1 patsiendil 20st) on ebanormaalsed maksanäitajad, väsimus, kõhulahtisus, iiveldus, oksendamine ja hüperglükeemia (vere suur glükoosisisaldus).
English: Zykadia was originally given ‘conditional approval' because there was more evidence to come about the medicine.
Estonian: Zykadia müügiluba anti esialgu tingimuslikult, sest ravimi toetuseks oodati täiendavaid andmeid.
English: In one study 56% of patients given Zykadia (92 of 163) were considered by the treating doctors to have shown a complete or partial response to the medicine.
Estonian: Ühes uuringus oli Zykadiat võtnud patsiente, kellel tekkis raviarstide hinnangul ravimile täielik või osaline ravivastus, 56% (92 patsienti 163st).
English: The doctor may decide to reduce the dose or stop treatment temporarily if side effects occur.
Estonian: Kõrvalnähtude ilmnemisel võib arst otsustada annust vähendada või ravi ajutiselt katkestada.
English: Zykadia has been shown to be effective at treating patients whose disease progressed during or shortly after treatment with crizotinib and who currently have very limited treatment options, as well as patients who have not been treated before.
Estonian: Zykadia efektiivsust tõendati patsientidel, kelle haigus progresseerus krisotiniibravi ajal või veidi pärast ravi ja kel on seni väga piiratud ravivõimalused.
English: For the full list of side effects and restrictions with Zykadia, see the package leaflet.
Estonian: Zykadia kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Response to treatment was assessed using body scans and standardised criteria used for solid tumours, with complete response being when the patient had no remaining signs of the cancer.
Estonian: Ravivastuse hindamiseks kasutati tomograafiauuringuid ja soliidtuumorite standardkriteeriume ning ravivastus oli täielik, kui patsiendil puudusid kõik vähinähud.
English: In patients with ALK-positive NSCLC, an abnormal form of ALK is produced that stimulates the cancer cells to divide and grow in an uncontrolled fashion.
Estonian: ALK-positiivse mitteväikerakkkopsuvähiga patsientidel tekib organismis ALKi ebanormaalne vorm, mis stimuleerib vähirakkude kontrollimatut jagunemist ja kasvu.
English: How does Zykadia work?
Estonian: Kuidas Zykadia toimib?
English: The active substance in Zykadia, ceritinib, works by blocking the activity of ALK, thereby reducing the growth and spread of the cancer.
Estonian: Zykadia toimeaine tseritiniib blokeerib ALKi toime, aeglustades nii vähi kasvu ja levikut.
English: Zykadia can only be obtained with a prescription and treatment must be started and supervised by a doctor who is experienced in using cancer medicines.
Estonian: Ravi peab alustama ja jälgima vähiravimite kasutamises kogenud arst.
English: How is Zykadia used?
Estonian: Kuidas Zykadiat kasutatakse?
English: Zykadia is a cancer medicine used on its own to treat adults with a type of lung cancer called nonsmall-cell lung cancer (NSCLC), when the disease is advanced.
Estonian: Zykadia on vähiravim, mida kasutatakse ainuravimina täiskasvanutel kaugelearenenud mitteväikerakkkopsuvähi (teatud tüüpi kopsuvähi) raviks.